PI3K pathway study in ER-positive, HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at a cell pathway called PI3K in breast cancer tissue to understand how it affects treatment response. It is for people with ER-positive, HER2-negative breast cancer who have received hormone therapy after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with invasive breast cancer
- Your tumor is ER-positive and HER2-negative
- You received hormone therapy (endocrine therapy) after surgery
- Your tumor tissue from a mastectomy is stored and available for testing
- Your medical records are complete and available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
This trial tests a combination of medications (inavolisib, pertuzumab, trastuzumab, and nab-paclitaxel) given before surgery to shrink tumors in people with HER2-positive early breast cancer that also has a specific gene change (PIK3CA mutation). The goal is to see if this treatment is effective and safe.
This Phase 1/2 trial tests how well a combination of targeted medicines works for advanced or returning HR+/HER2- breast cancer that has a PI3K pathway change (such as PIK3CA, PTEN, or AKT1). It may help by blocking growth signals in the cancer and is especially for people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Hear when a new Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.